403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Cardiol Therapeutics Inc.
(MENAFN- Baystreet) 09:42 AM EST - Cardiol Therapeutics Inc.: Announced that it has surpassed 50% patient enrollment in MAVERIC, its Phase III randomized, double-blind, placebo-controlled, multi-center international trial evaluating CardiolRxTM for the prevention of disease recurrence in patients with recurrent pericarditis. Cardiol Therapeutics Inc.
shares T are trading unchanged at $1.35.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment